Comparative Pharmacology
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus NAYZILAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus NAYZILAM.
FLURAZEPAM HYDROCHLORIDE vs NAYZILAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
Nayzilam (midazolam) is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal activity.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
5 mg intranasally as a single dose; may repeat once after 10 minutes if needed. Maximum 10 mg per episode.
None Documented
None Documented
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Terminal elimination half-life of midazolam is 1.5–2.5 hours, but for NAYZILAM (midazolam nasal spray) the effective half-life for anticonvulsant effect is approximately 2–3 hours due to prolonged absorption; clinical context: used for seizure clusters, duration of effect may persist for 4–6 hours.
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Renal excretion as metabolites (primarily glucuronide conjugates) and unchanged drug; approximately 15% recovered in urine as unchanged midazolam, with the remainder as metabolites; <1% excreted in feces via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine